BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 34062932)

  • 1. Genetic Alterations and Therapeutic Targeting of Philadelphia-Like Acute Lymphoblastic Leukemia.
    Iacobucci I; Roberts KG
    Genes (Basel); 2021 May; 12(5):. PubMed ID: 34062932
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The biology of Philadelphia chromosome-like ALL.
    Roberts KG
    Best Pract Res Clin Haematol; 2017 Sep; 30(3):212-221. PubMed ID: 29050694
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Beyond Philadelphia: 'Ph-like' B cell precursor acute lymphoblastic leukemias - diagnostic challenges and therapeutic promises.
    Izraeli S
    Curr Opin Hematol; 2014 Jul; 21(4):289-96. PubMed ID: 24848770
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Philadelphia Chromosome-like Acute Lymphoblastic Leukemia.
    Pui CH; Roberts KG; Yang JJ; Mullighan CG
    Clin Lymphoma Myeloma Leuk; 2017 Aug; 17(8):464-470. PubMed ID: 28842136
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BCR/ABL1-like acute lymphoblastic leukemia: How to diagnose and treat?
    Chiaretti S; Messina M; Foà R
    Cancer; 2019 Jan; 125(2):194-204. PubMed ID: 30561755
    [TBL] [Abstract][Full Text] [Related]  

  • 6. JAK mutations in high-risk childhood acute lymphoblastic leukemia.
    Mullighan CG; Zhang J; Harvey RC; Collins-Underwood JR; Schulman BA; Phillips LA; Tasian SK; Loh ML; Su X; Liu W; Devidas M; Atlas SR; Chen IM; Clifford RJ; Gerhard DS; Carroll WL; Reaman GH; Smith M; Downing JR; Hunger SP; Willman CL
    Proc Natl Acad Sci U S A; 2009 Jun; 106(23):9414-8. PubMed ID: 19470474
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Why and how to treat Ph-like ALL?
    Roberts KG
    Best Pract Res Clin Haematol; 2018 Dec; 31(4):351-356. PubMed ID: 30466746
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Philadelphia chromosome-like acute lymphoblastic leukemia: progress in a new cancer subtype.
    Wells J; Jain N; Konopleva M
    Clin Adv Hematol Oncol; 2017 Jul; 15(7):554-561. PubMed ID: 28749919
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting Kinase-activating Genetic Lesions to Improve Therapy of Pediatric Acute Lymphoblastic Leukemia.
    Franca R; Kuzelicki NK; Sorio C; Toffoletti E; Montecchini O; Poropat A; Rabusin M; Curci D; Paladin D; Stocco G; Decorti G
    Curr Med Chem; 2018; 25(24):2811-2825. PubMed ID: 28748759
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rapid molecular response to dasatinib in Ph-like acute lymphoblastic leukemia patients with ABL1 rearrangements: case series and literature review.
    Tan KW; Zhu YY; Qiu QC; Wang M; Shen HJ; Huang SM; Cao HY; Wan CL; Li YY; Dai HP; Xue SL
    Ann Hematol; 2023 Sep; 102(9):2397-2402. PubMed ID: 37103615
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BCR-ABL1-like acute lymphoblastic leukaemia: From bench to bedside.
    Boer JM; den Boer ML
    Eur J Cancer; 2017 Sep; 82():203-218. PubMed ID: 28709134
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Philadelphia chromosome-like acute lymphoblastic leukemia.
    Tasian SK; Loh ML; Hunger SP
    Blood; 2017 Nov; 130(19):2064-2072. PubMed ID: 28972016
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR-ABL1 and its resistance and compound mutants BCR-ABL1
    Mian AA; Haberbosch I; Khamaisie H; Agbarya A; Pietsch L; Eshel E; Najib D; Chiriches C; Ottmann OG; Hantschel O; Biondi RM; Ruthardt M; Mahajna J
    Ann Hematol; 2021 Aug; 100(8):2023-2029. PubMed ID: 34110462
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Philadelphia chromosome-like acute lymphoblastic leukemia: A review of the genetic basis, clinical features, and therapeutic options.
    Khan M; Siddiqi R; Tran TH
    Semin Hematol; 2018 Oct; 55(4):235-241. PubMed ID: 30502852
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical impact of ABL1 kinase domain mutations and IKZF1 deletion in adults under age 60 with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL): molecular analysis of CALGB (Alliance) 10001 and 9665.
    DeBoer R; Koval G; Mulkey F; Wetzler M; Devine S; Marcucci G; Stone RM; Larson RA; Bloomfield CD; Geyer S; Mullighan CG; Stock W
    Leuk Lymphoma; 2016 Oct; 57(10):2298-306. PubMed ID: 26892479
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tyrosine kinase inhibitor response of ABL-class acute lymphoblastic leukemia: the role of kinase type and SH3 domain.
    van Outersterp I; Tasian SK; Reichert CEJ; Boeree A; de Groot-Kruseman HA; Escherich G; Boer JM; den Boer ML
    Blood; 2024 May; 143(21):2178-2189. PubMed ID: 38394665
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How is the Ph-like signature being incorporated into ALL therapy?
    Maese L; Tasian SK; Raetz EA
    Best Pract Res Clin Haematol; 2017 Sep; 30(3):222-228. PubMed ID: 29050695
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BCR/ABL1-Like Acute Lymphoblastic Leukemia: From Diagnostic Approaches to Molecularly Targeted Therapy.
    Płotka A; Lewandowski K
    Acta Haematol; 2022; 145(2):122-131. PubMed ID: 34818644
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemotherapy Resistance in B-ALL with Cryptic NUP214-ABL1 Is Amenable to Kinase Inhibition and Immunotherapy.
    Nardi V; McAfee SL; Dal Cin P; Tsai HK; Amrein PC; Hobbs GS; Brunner AM; Narayan R; Foster J; Fathi AT; Hock H
    Oncologist; 2022 Mar; 27(2):82-86. PubMed ID: 35641210
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia.
    Roberts KG; Li Y; Payne-Turner D; Harvey RC; Yang YL; Pei D; McCastlain K; Ding L; Lu C; Song G; Ma J; Becksfort J; Rusch M; Chen SC; Easton J; Cheng J; Boggs K; Santiago-Morales N; Iacobucci I; Fulton RS; Wen J; Valentine M; Cheng C; Paugh SW; Devidas M; Chen IM; Reshmi S; Smith A; Hedlund E; Gupta P; Nagahawatte P; Wu G; Chen X; Yergeau D; Vadodaria B; Mulder H; Winick NJ; Larsen EC; Carroll WL; Heerema NA; Carroll AJ; Grayson G; Tasian SK; Moore AS; Keller F; Frei-Jones M; Whitlock JA; Raetz EA; White DL; Hughes TP; Guidry Auvil JM; Smith MA; Marcucci G; Bloomfield CD; Mrózek K; Kohlschmidt J; Stock W; Kornblau SM; Konopleva M; Paietta E; Pui CH; Jeha S; Relling MV; Evans WE; Gerhard DS; Gastier-Foster JM; Mardis E; Wilson RK; Loh ML; Downing JR; Hunger SP; Willman CL; Zhang J; Mullighan CG
    N Engl J Med; 2014 Sep; 371(11):1005-15. PubMed ID: 25207766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.